Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Common Equity (2020 - 2025)

iSpecimen has reported Common Equity over the past 6 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Common Equity at $3.1 million for Q4 2025, down 6.73% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (down 6.73% YoY), and the annual figure for FY2025 was $3.1 million, down 6.73%.
  • Common Equity for Q4 2025 was $3.1 million at iSpecimen, up from $3.1 million in the prior quarter.
  • Over the last five years, Common Equity for ISPC hit a ceiling of $29.8 million in Q4 2021 and a floor of -$31.2 million in Q1 2021.
  • Median Common Equity over the past 5 years was $10.2 million (2021), compared with a mean of $10.1 million.
  • Biggest five-year swings in Common Equity: skyrocketed 209.21% in 2021 and later tumbled 89.79% in 2025.
  • iSpecimen's Common Equity stood at $29.8 million in 2021, then tumbled by 31.83% to $20.3 million in 2022, then plummeted by 52.04% to $9.7 million in 2023, then tumbled by 66.01% to $3.3 million in 2024, then dropped by 6.73% to $3.1 million in 2025.
  • The last three reported values for Common Equity were $3.1 million (Q4 2025), $3.1 million (Q3 2025), and $621973.0 (Q2 2025) per Business Quant data.